Literature DB >> 1696193

Cell adhesion mechanisms and their potential impact on wound healing and tumor control.

R Rudolph1, D Cheresh.   

Abstract

Cells attach to surrounding extracellular protein matrix via structural receptors called integrins. Many of the integrins attach to a specific amino acid sequence in structural proteins, that of arginine-glycine-aspartic acid (RGD). These structural receptors are composed of alpha and beta subunits, which vary depending on which cells are involved and on which specific protein is to be bound. The integrin-matrix bond can be inhibited by monoclonal antibodies directed against receptor subunits, or by synthetic proteins (peptides) that contain the RGD sequence. This inhibition of cell adhesion has important potential for cellular control of all phases of wound healing, as well as of malignant cell growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696193

Source DB:  PubMed          Journal:  Clin Plast Surg        ISSN: 0094-1298            Impact factor:   2.017


  3 in total

1.  Role of the alpha v-integrin subunit in cell proliferation, apoptosis and tumor metastasis of laryngeal and hypopharyngeal squamous cell carcinomas: a clinical and in vitro investigation.

Authors:  Jian Guang Lu; Ya Nan Sun; Chao Wang; De Jun Jin; Ming Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-04-22       Impact factor: 2.503

2.  Altered expression pattern of integrin alphavbeta3 correlates with actin cytoskeleton in primary cultures of human breast cancer.

Authors:  Sophia Havaki; Mirsini Kouloukoussa; Kawther Amawi; Yiannis Drosos; Leonidas D Arvanitis; Nikos Goutas; Dimitrios Vlachodimitropoulos; Stamatis D Vassilaros; Eleni Z Katsantoni; Irene Voloudakis-Baltatzis; Vassiliki Aleporou-Marinou; Christos Kittas; Evangelos Marinos
Journal:  Cancer Cell Int       Date:  2007-10-02       Impact factor: 5.722

3.  Bioaccessibility of Shore Magic® collagen, a low-molecular-weight collagen supplement, in different in vitro barrier models.

Authors:  Marcel Benadiba; Raphael Serruya; Yehoshua Maor
Journal:  Heliyon       Date:  2018-09-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.